Agenesis of dorsal pancreas in a patient with weight loss and diabetes mellitus

1994 ◽  
Vol 39 (8) ◽  
pp. 1708-1713 ◽  
Author(s):  
Walter A. Klein ◽  
Marta A. Dabezies ◽  
Arnold C. Friedman ◽  
Dina F. Caroline ◽  
Guenther H. Boden ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Weight Loss ◽  
Dorsal Pancreas ◽  
Agenesis Of Dorsal Pancreas

scholarly journals Agenesis of dorsal pancreas in a young adult: a rare cause of diabetes mellitus

2018 ◽  
pp. bcr-2017-223301 ◽  
Author(s):  
Satyendra Kumar Sonkar ◽  
Satish Kumar ◽  
Neeraj Kumar Singh
Keyword(s):  
Diabetes Mellitus ◽  
Young Adult ◽  
Dorsal Pancreas ◽  
Agenesis Of Dorsal Pancreas

scholarly journals A Rare Case of Agenesis of Dorsal Pancreas

2012 ◽  
Vol 01 (01) ◽  
pp. 036-039
Author(s):  
Devi Jansirani D. ◽  
Shiva deep S. ◽  
Deepak Barathi S.
Keyword(s):  
Diabetes Mellitus ◽  
Computed Tomography ◽  
Congenital Anomaly ◽  
Rare Case ◽  
Splenic Vein ◽  
Uncinate Process ◽  
Present Patient ◽  
Rare Congenital Anomaly ◽  
Dorsal Pancreas ◽  
Agenesis Of Dorsal Pancreas

AbstractAgenesis of dorsal bud of the pancreas is an extremely rare congenital anomaly which results in absence of neck, body and tail of the adult pancreas. It may be associated with number of clinical features like diabetes mellitus, abdominal pain and chronic pancreatitis. Because of its rarity, we are reporting a case of agenesis of dorsal pancreas associated with early onset diabetes. Ultrasonography and Computed tomography showed absence of neck, body and tail of pancreas anterior to splenic vein and portal confluence; however head and uncinate process were normally present. Patient was thus diagnosed as agenesis of dorsal bud of pancreas.

TYPE 2 DIABETES MELLITUS REMISSION AND ITS PREDICTION AFTER TWO-STAGE SURGICAL TREATMENT OF PATIENTS WITH MORBID OBESITY

2019 ◽  
Vol 72 (5) ◽  
pp. 739-743
Author(s):  
Oleksandr Yu. Ioffe ◽  
Mykola S. Kryvopustov ◽  
Yuri A. Dibrova ◽  
Yuri P. Tsiura
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Type 2 Diabetes Mellitus ◽  
Surgical Treatment ◽  
Two Stage ◽  
C Peptide ◽  
Peptide Level

Introduction: Morbid obesity (MO) has a significant impact on mortality, health and quality of life of patients. Type 2 diabetes mellitus (T2DM) is a common comorbidity in patients with MO. The aim is to study T2DM remission and to develop a prediction model for T2DM remission after two-stage surgical treatment of patients with MO. Materials and methods: The study included 97 patients with MO. The mean BMI was 68.08 (95% CI: 66.45 - 69.71) kg/m2. 70 (72,2%) patients with MO were diagnosed with T2DM. The first stage of treatment for the main group (n=60) included the IGB placement, for the control group (n=37) - conservative therapy. In the second stage of treatment the patients underwent bariatric surgery. The study addresses such indicators as BMI, percentage of weight loss, percentage of excess weight loss, ASA physical status class, fasting glucose level, HbA1c, C-peptide. Results: Two-stage treatment of morbidly obese patients with T2DM promotes complete T2DM remission in 68.1% of patients. The risk prediction model for failure to achieve complete T2DM remission 12 months after LRYGB based on a baseline C-peptide level has a high predictive value, AUC = 0.84 (95% CI: 0.69-0.93), OR = 0.23 ( 95% CI: 0.08-0.67). Conclusions: Two-stage treatment of patients with MO promotes improvement of carbohydrate metabolism indicators. With a C-peptide level > 3.7 ng/ml, prediction of complete T2DM remission 12 months after Laparoscopic Roux-en-Y Gastric Bypass is favorable.

scholarly journals Chromium and cobalt intoxication mimicking mitochondriopathy

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Tim W. Rattay ◽  
Torsten Kluba ◽  
Ludger Schöls
Keyword(s):  
Diabetes Mellitus ◽  
Weight Loss ◽  
Mitochondrial Dna ◽  
Wear Debris ◽  
Hip Prosthesis ◽  
Mitochondrial Cytopathy ◽  
Whole Exome ◽  
Metal On Metal ◽  
Metal Wear ◽  
History Of

AbstractA 53-year old male with a history of progressive visual impairment, hearing loss, peripheral neuropathy, poorly controlled diabetes mellitus, cardiomyopathy, and weight loss was referred to the rare disease center due to the suspicion of mitochondrial cytopathy. In line with mitochondrial dysfunction, lactate in CSF was increased. Genetic testing by whole-exome sequencing and mitochondrial DNA did not reveal a likely cause. The case remained unsolved until he developed pain in his right hip, where he had received total hip arthroplasty 12 years earlier. An orthopedic evaluation revealed substantial shrinkage of the head of the hip prosthesis. Due to metal-on-metal wear, debris chromium and cobalt levels in serum were massively increased and significantly improved with multisystemic impairment after exchanging the defective implant.

scholarly journals Incretin-Based Therapies in Type 2 Diabetes Mellitus

2008 ◽  
Vol 93 (10) ◽  
pp. 3703-3716 ◽  
Author(s):  
Chee W. Chia ◽  
Josephine M. Egan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Type 2 Diabetes Mellitus ◽  
Evidence Synthesis ◽  
Glycosylated Hemoglobin ◽  
Cell Mass ◽  
New Drugs ◽  
Medline Search

Context: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide are incretins secreted from enteroendocrine cells postprandially in part to regulate glucose homeostasis. Dysregulation of these hormones is evident in type 2 diabetes mellitus (T2DM). Two new drugs, exenatide (GLP-1 mimetic) and sitagliptin [dipeptidyl peptidase (DPP) 4 inhibitor], have been approved by regulatory agencies for treating T2DM. Liraglutide (GLP-1 mimetic) and vildagliptin (DPP 4 inhibitor) are expected to arrive on the market soon. Evidence Acquisition: The background of incretin-based therapy and selected clinical trials of these four drugs are reviewed. A MEDLINE search was conducted for published articles using the key words incretin, glucose-dependent insulinotropic polypeptide, GLP-1, exendin-4, exenatide, DPP 4, liraglutide, sitagliptin, and vildagliptin. Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year follow-up data on exenatide showed a sustained weight loss and glycosylated hemoglobin (HbA1c) reduction of 1%. Nausea and vomiting are common. Results from phase 3 studies are pending on liraglutide. Sitagliptin and vildagliptin are orally active. In 24-wk studies, sitagliptin reduces HbA1c by 0.6–0.8% as monotherapy, 1.8% as initial combination therapy with metformin, and 0.7% as add-on therapy to metformin. Vildagliptin monotherapy lowered HbA1c by 1.0–1.4% after 24 wk. Their major side effects are urinary tract and nasopharyngeal infections and headaches. Exenatide and liraglutide cause weight loss, whereas sitagliptin and vildagliptin do not. Conclusions: The availability of GLP-1 mimetics and DPP 4 inhibitors has increased our armamentarium for treating T2DM. Unresolved issues such as the effects of GLP-1 mimetics and DPP 4 inhibitors on β-cell mass, the mechanism by which GLP-1 mimetics lowers glucagon levels, and exactly how DPP 4 inhibitors lead to a decline in plasma glucose levels without an increase in insulin secretion, need further research.

Sign in / Sign up

Export Citation Format

Share Document